FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983523128> ?p ?o ?g. }

• W2983523128 endingPage "19" @default.
• W2983523128 startingPage "19" @default.
• W2983523128 abstract "Follicular Lymphoma (FL) is the most common indolent lymphoma derived from light zone germinal center B cells and characterized by a t(14;18) translocation resulting in upregulation of BCL2 in over 80% of cases. This translocation alone is not sufficient for tumorogenesis, and must be combined with additional genetic mutations to transform B cells. FL is incurable and the disease course can be highly varied, with survival ranging from a few months to decades following diagnosis and treatment with standard chemoimmunotherapy. The heterogeneity of FL poses major challenges to identifying the association of genetic alterations and clinical outcome. Current WHO guidelines recommend establishing grade for each FL case with grade 3 thought to be more aggressive than 1 and 2. The genetic basis and clinical implications of grade in FL are unclear. Recent sequencing studies have identified many genes found to be recurrently mutated in FL including KMT2D and CREBBP. However, the degree to which genetic alterations cooperate with each other or contribute to clinical outcome is unclear. Based on the observed mutational rates in follicular lymphoma, we estimated 900 cases were needed to comprehensively delineate the genetic alterations that underlie histologic grade and clinical outcome. Accordingly, we enrolled a cohort of 1042 patients with newly diagnosed FL. All treated patients received rituximab-containing standard regimens. To go beyond the identification of gene-coding events, we developed a very large panel of 110 Mbp covering exonic (~40Mbp) and non-exonic regions (~70Mbp) of interest to enable a wide range of genomic analysis including mutation calling in both coding and non-coding regions, rearrangement detection, viral identification, and copy number analysis. In addition to the whole exome, we extended coverage to include introns, promoters, and untranslated regions of all known driver genes in cancer. We included the entirety of the immunoglobulin loci, T-cell receptor loci and CD3 loci to detect clonotypes and rearrangements. We also included lymphoma-relevant long non-coding RNAs, microRNAs, enhancers, and breakpoint-prone regions. For viral detection, we targeted the genomes of eight cancer-related viruses: Epstein-Barr virus, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, Kaposi's sarcoma-associated herpesvirus, human T-lymphotropic virus, and Merkel cell polyomavirus. In addition, to enable high resolution identification of copy number variation (CNV) calls, the entire genome was tiled with probes spaced 10kb apart. DNA and RNA were extracted from all tumors and their paired normal samples, prepared into DNA and RNA sequencing libraries and subjected to sequencing on the Illumina platform to a targeted coverage of 150X. Somatic events were identified and further filtered to identify driver events in both coding and non-coding regions. FLs demonstrated a significant degree of genetic heterogeneity with over 100 genes mutated with a frequency of at least 2%. Nearly 100% of FL cases had a mutation in at least one chromatin-modifying gene. The most frequently mutated genes in follicular lymphoma were KMT2D, BCL2, IGLL5 and CREBBP. In addition, we identified frequent mutations in SPEN, BIRC6 and SETD2. To our knowledge, this is the first description of alterations in these genes in FL. Transcriptome analysis indicated a strong correlation between BIRC6 mutations and the previously described immune response 2 signature that is associated with a poor prognosis. We further performed unbiased clustering of genetic alterations in these FL cases. We identified a cluster that was specifically enriched in BCL6 and TP53 alterations and was strongly associated with grade 3 FLs which are predicted to have poorer outcomes with low intensity therapies. We further examined the genetic profiles of 1001 DLBCLs in comparison to this cohort of FLs. Our data indicate a continuum of highly overlapping genetic alterations with DLBCL displaying more complex patterns that included alterations in MYC, TP53 and CDKN2A (mainly copy number losses), indicating shared pathogenetic mechanisms underlying FL and DLBCL, particularly those germinal center B cell origin. Disclosures Koff: Burroughs Wellcome Fund: Research Funding; V Foundation: Research Funding; Lymphoma Research Foundation: Research Funding; American Association for Cancer Research: Research Funding. Leppä:Roche: Honoraria, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen-Cilag: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees. Gang:ROCHE: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Hsi:Abbvie: Research Funding; Eli Lilly: Research Funding; Cleveland Clinic&Abbvie Biotherapeutics Inc: Patents & Royalties: US8,603,477 B2; Jazz: Consultancy. Flowers:AbbVie: Consultancy, Research Funding; Denovo Biopharma: Consultancy; BeiGene: Consultancy, Research Funding; Burroughs Wellcome Fund: Research Funding; Eastern Cooperative Oncology Group: Research Funding; National Cancer Institute: Research Funding; V Foundation: Research Funding; Optimum Rx: Consultancy; Millenium/Takeda: Research Funding; TG Therapeutics: Research Funding; Gilead: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Karyopharm: Consultancy; AstraZeneca: Consultancy; Pharmacyclics/Janssen: Consultancy, Research Funding; Spectrum: Consultancy; Bayer: Consultancy; Acerta: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Consultancy, Research Funding. Neff:Enzyvant: Consultancy; EUSA Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees. Fedoriw:Alexion Pharmaceuticals: Other: Consultant and Speaker. Reddy:Genentech: Research Funding; BMS: Consultancy, Research Funding; Celgene: Consultancy; KITE Pharma: Consultancy; Abbvie: Consultancy. Mason:Sysmex: Honoraria. Behdad:Loxo-Bayer: Membership on an entity's Board of Directors or advisory committees; Thermo Fisher: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Speaker. Burton:Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Dave:Data Driven Bioscience: Equity Ownership." @default.
• W2983523128 created "2019-11-22" @default.
• W2983523128 creator A5002839023 @default.
• W2983523128 creator A5004518762 @default.
• W2983523128 creator A5005165049 @default.
• W2983523128 creator A5005168764 @default.
• W2983523128 creator A5006583715 @default.
• W2983523128 creator A5007853425 @default.
• W2983523128 creator A5008732947 @default.
• W2983523128 creator A5009137826 @default.
• W2983523128 creator A5009514082 @default.
• W2983523128 creator A5010699801 @default.
• W2983523128 creator A5010756701 @default.
• W2983523128 creator A5010894023 @default.
• W2983523128 creator A5011599008 @default.
• W2983523128 creator A5012414670 @default.
• W2983523128 creator A5013263576 @default.
• W2983523128 creator A5014966517 @default.
• W2983523128 creator A5016992044 @default.
• W2983523128 creator A5017976619 @default.
• W2983523128 creator A5024601733 @default.
• W2983523128 creator A5025928549 @default.
• W2983523128 creator A5026011719 @default.
• W2983523128 creator A5027080346 @default.
• W2983523128 creator A5028515198 @default.
• W2983523128 creator A5029491549 @default.
• W2983523128 creator A5030353708 @default.
• W2983523128 creator A5031551892 @default.
• W2983523128 creator A5031844434 @default.
• W2983523128 creator A5035085056 @default.
• W2983523128 creator A5035638668 @default.
• W2983523128 creator A5036369018 @default.
• W2983523128 creator A5038345056 @default.
• W2983523128 creator A5040843582 @default.
• W2983523128 creator A5042334602 @default.
• W2983523128 creator A5044506875 @default.
• W2983523128 creator A5045281097 @default.
• W2983523128 creator A5045622683 @default.
• W2983523128 creator A5047318164 @default.
• W2983523128 creator A5048472560 @default.
• W2983523128 creator A5051888634 @default.
• W2983523128 creator A5053275663 @default.
• W2983523128 creator A5055183115 @default.
• W2983523128 creator A5058837031 @default.
• W2983523128 creator A5059878993 @default.
• W2983523128 creator A5062045024 @default.
• W2983523128 creator A5062450282 @default.
• W2983523128 creator A5063046732 @default.
• W2983523128 creator A5064643006 @default.
• W2983523128 creator A5064702056 @default.
• W2983523128 creator A5065696758 @default.
• W2983523128 creator A5067695671 @default.
• W2983523128 creator A5069364438 @default.
• W2983523128 creator A5069390152 @default.
• W2983523128 creator A5070011974 @default.
• W2983523128 creator A5070181461 @default.
• W2983523128 creator A5072747994 @default.
• W2983523128 creator A5072977407 @default.
• W2983523128 creator A5073890024 @default.
• W2983523128 creator A5075581216 @default.
• W2983523128 creator A5080038116 @default.
• W2983523128 creator A5080939807 @default.
• W2983523128 creator A5081219793 @default.
• W2983523128 creator A5081888684 @default.
• W2983523128 creator A5082892912 @default.
• W2983523128 creator A5083592086 @default.
• W2983523128 creator A5084525969 @default.
• W2983523128 creator A5085325467 @default.
• W2983523128 creator A5086733615 @default.
• W2983523128 creator A5087061397 @default.
• W2983523128 creator A5087568984 @default.
• W2983523128 creator A5088101785 @default.
• W2983523128 creator A5088958720 @default.
• W2983523128 creator A5089386265 @default.
• W2983523128 creator A5090168111 @default.
• W2983523128 creator A5090832029 @default.
• W2983523128 creator A5091838077 @default.
• W2983523128 date "2019-11-13" @default.
• W2983523128 modified "2023-10-17" @default.
• W2983523128 title "Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma" @default.
• W2983523128 doi "https://doi.org/10.1182/blood-2019-130255" @default.
• W2983523128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31723982" @default.
• W2983523128 hasPublicationYear "2019" @default.
• W2983523128 type Work @default.
• W2983523128 sameAs 2983523128 @default.
• W2983523128 citedByCount "3" @default.
• W2983523128 countsByYear W29835231282020 @default.
• W2983523128 countsByYear W29835231282021 @default.
• W2983523128 crossrefType "journal-article" @default.
• W2983523128 hasAuthorship W2983523128A5002839023 @default.
• W2983523128 hasAuthorship W2983523128A5004518762 @default.
• W2983523128 hasAuthorship W2983523128A5005165049 @default.
• W2983523128 hasAuthorship W2983523128A5005168764 @default.
• W2983523128 hasAuthorship W2983523128A5006583715 @default.
• W2983523128 hasAuthorship W2983523128A5007853425 @default.
• W2983523128 hasAuthorship W2983523128A5008732947 @default.
• W2983523128 hasAuthorship W2983523128A5009137826 @default.
• W2983523128 hasAuthorship W2983523128A5009514082 @default.

• next